CClinicalTrials.gg
Not yet recruitingNCT07760558Updated Aug 12, 2026

COLORS-Validate Study of Decision-Support Software for Surgical Sequencing in Colorectal Liver Metastases

An observational study in Colorectal Liver Metastases, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates a surgical decision-support software designed to assist physicians in selecting the optimal surgical sequence for patients with colorectal cancer liver metastases.

In this multicenter prospective simulation study, participating surgeons from multiple centers will review standardized clinical case scenarios. For each case, physicians will first make a surgical sequencing decision based on their own clinical judgment. They will then review the recommendation provided by the decision-support software and make a second decision if they choose to revise their initial plan.

The study will assess whether the software influences clinical decision-making, including changes in surgical strategy, decision confidence, decision time, and agreement with software recommendations. Physician user experience will also be evaluated using standardized questionnaires, including system usability and cognitive workload scales.

The goal of this study is to determine the clinical utility and usability of the decision-support software in improving surgical decision-making consistency and supporting clinical reasoning in colorectal liver metastases cases.

Read the detailed description

The selection of surgical sequencing-whether to resect the primary tumor first or the liver metastases first-in patients with colorectal cancer liver metastases (CRLM) undergoing synchronous resection represents a critical and highly complex decision in current clinical practice. With the advancement of systemic therapies and surgical techniques, an increasing number of patients with initially unresectable CRLM have gained the opportunity for surgical treatment. However, due to substantial heterogeneity among patients in terms of tumor burden, biological behavior of the disease, and overall physical condition, no unified standard currently exists for determining the optimal surgical sequence. Existing studies comparing different surgical strategies have yielded inconsistent prognostic results, and most are based on retrospective analyses lacking consistent conclusions and clear stratification criteria. Consequently, in real-world clinical practice, such decisions rely heavily on physician experience and institutional preference, resulting in considerable inter-physician variability and uncertainty. This scenario, characterized by the absence of a clearly optimal strategy, renders the decision-making process inherently a form of decision-making under uncertainty.

Based on this context, we previously developed, using multicenter retrospective data, two multi-outcome predictive models corresponding to different surgical strategies. These models integrate postoperative major complications, Comprehensive Complication Index (CCI), progression-free survival (PFS), and overall survival (OS), and have been externally validated. However, in real-world clinical decision-making, the central challenge faced by surgeons is not merely the prediction of a single outcome, but rather the need to balance multiple competing outcomes. For example, one surgical strategy may be associated with a lower risk of postoperative complications but limited long-term survival benefit, whereas another may involve higher perioperative risk in exchange for improved oncological outcomes. This inherent tension among multidimensional outcomes transforms clinical decision-making into a multi-objective decision-making problem, rather than a simple comparison of a single endpoint.

In current practice, such trade-offs across outcomes are typically based on physicians' experiential judgment, whereby the relative importance of different outcomes is implicitly weighted. However, this weighting process lacks explicit representation and standardized criteria, and is prone to influence by individual experience, risk preference, and institutional norms, thereby leading to substantial variability and inconsistency in decision-making. To address this key limitation, the present study further constructs a structured multi-outcome weighting framework using the Delphi method combined with the analytic hierarchy process (AHP). This approach establishes the relative importance of different clinical outcomes through expert consensus and translates it into a quantifiable weighting system, thereby enabling the integration of multidimensional predictive results into a comparable composite score. Based on this framework, we developed a decision-support software system capable of simultaneously providing individualized multi-outcome predictions and composite reference scores, transforming the previously experience-dependent implicit trade-off process into a transparent, interpretable, and standardized decision-support process.

Nevertheless, the establishment of predictive models and weighting frameworks does not necessarily translate into practical clinical value. For decision-support systems, focusing solely on predictive performance is insufficient to reflect their real-world clinical utility. More importantly, it is necessary to evaluate whether such systems can influence physician decision-making behavior under uncertainty, reduce unnecessary variability, and provide a structured reference framework for decision-making. In addition, because clinical decision-making involves counterfactual comparisons (i.e., potential outcomes under alternative strategies for the same patient cannot be simultaneously observed), traditional outcome-based evaluation methods have inherent limitations. Therefore, it is necessary to adopt a model-informed standardized reference framework to evaluate the impact of AI assistance at the level of decision behavior.

Based on the above considerations, this study adopts a multicenter, prospective crossover simulation design to systematically evaluate the clinical utility of the decision-support system in a standardized setting. The evaluation focuses on the following two dimensions:

  1. From a scientific decision perspective: whether the system alters physician decision behavior, improves decision consistency, and reduces variability;
  2. From a human factors perspective: whether the system affects cognitive load, decision confidence, and user experience.

This study extends AI evaluation beyond predictive performance toward its influence on decision-making behavior, with a particular focus on the human-AI collaborative decision-making process in uncertain clinical scenarios.

02

Conditions studied

  • Colorectal Liver Metastases
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study will enroll physicians from three tertiary academic medical centers in China, including hepatobiliary surgeons and colorectal surgeons with varying levels of clinical experience. Participants will be required to complete standardized simulation-based case evaluations involving surgical decision-making for colorectal cancer liver metastases. The study aims to assess changes in decision-making behavior, confidence, and usability of a decision-support software system.

Inclusion criteria

  • Licensed physicians specializing in hepatobiliary surgery or colorectal surgery
  • At least 1 year of clinical experience after graduation
  • Willing to participate in the simulation-based decision-making study
  • Practicing at one of the participating tertiary academic hospitals

Exclusion criteria

Exclusion Criteria:

  • Not actively involved in clinical surgical decision-making
  • Unable to complete all required simulation sessions
  • Prior involvement in the development of the decision-support software
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No

Groups and cohorts

  • Unaided Clinical Decision-Making

    Physicians make surgical sequencing decisions based on routine clinical judgment without decision-support software.

    Other: Unaided Clinical Decision-Making

  • Decision-Support Software-Assisted Decision-Making

    Physicians make surgical sequencing decisions after reviewing recommendations from the decision-support software.

    Other: Software-Assisted Clinical Decision-Making

Interventions

  • OtherUnaided Clinical Decision-Making

    Usual Clinical Decision-Making (Without Decision Support Software)

  • OtherSoftware-Assisted Clinical Decision-Making

    Physicians make surgical sequencing decisions after reviewing recommendations generated by the decision-support software, including weighted scores and predicted outcomes.

05

What researchers measure

Primary outcomes

  1. Change in Surgical Decision-Making Between Software-Assisted and Non-Assisted Conditions

    The primary outcome is the proportion of cases in which physicians change their surgical sequencing decision after reviewing decision-support software recommendations compared with their initial unaided decision.

    Time frame: During each simulated case evaluation session

Secondary outcomes

  1. Software utilization outcomes

    Software adoption rate (agreement between final decision and software recommendation); Post-change adoption rate among changed decisions

    Time frame: During each simulated case evaluation session

  2. Decision performance outcomes

    Decision-making time (seconds per case); Inter-group comparison between unaided and software-assisted conditions

    Time frame: During each simulated case evaluation session

  3. Human factors outcomes

    Decision confidence score (5-point Likert scale)

    Time frame: During each simulated case evaluation session

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Chen Q, Chen J, Deng Y, Bi X, Zhao J, Zhou J, Huang Z, Cai J, Xing B, Li Y, Li K, Zhao H. Personalized prediction of postoperative complication and survival among Colorectal Liver Metastases Patients Receiving Simultaneous Resection using machine learning approaches: A multi-center study. Cancer Lett. 2024 Jul 1;593:216967. doi: 10.1016/j.canlet.2024.216967. Epub 2024 May 18. PubMed 38768679 ↗
  • Chen Q, Tong J, Deng Y, Bi X, Li Y, Li K, Zhao H. Impact of an AI prognostic tool on clinician performance in colorectal liver metastases. NPJ Digit Med. 2026 Apr 8;9(1):432. doi: 10.1038/s41746-026-02606-5. PubMed 41951838 ↗
  • Chen Q, Deng Y, Wang K, Li Y, Bi X, Li K, Zhao H. Dynamic Prognostic Models for Colorectal Cancer With Liver Metastases. JAMA Netw Open. 2025 Aug 1;8(8):e2529093. doi: 10.1001/jamanetworkopen.2025.29093. PubMed 40864468 ↗

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared because of participant confidentiality, institutional data-protection requirements, and the potential risk of re-identification given the characteristics and size of the study population. Aggregate study results will be reported in peer-reviewed publications.

08

Registry details

Key details

Study ID
NCT07760558
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Aug 12, 2026

Study contacts

Hong Zhao, MD
Contact
tongjinliang0202@126.com
+86 01087787100
QICHEN CHEN, MD
Contact
chenqichen0822@126.com
+86101881055
Hong Zhao, MD
study chair · Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion